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The sphincter of Oddi (SO) is a smooth muscle valve regulating the flow of biliary and 
pancreatic secretions into the duodenum, initially described in 1887 by the Italian anato-
mist, Ruggero Oddi. SO dysfunction (SOD) is a broad term referring to numerous biliary, 
pancreatic, and hepatic disorders resulting from spasms, strictures, and relaxation of 
this valve at inappropriate times. This review brings attention to various factors that may 
increase the risk of SOD, including but not limited to: cholecystectomy, opiates, and 
alcohol. Lack of proper recognition and treatment of SOD may be associated with clin-
ical events, including pancreatitis and biliary symptoms with hepatic enzyme elevation. 
Pharmacologic and non-pharmacologic approaches are discussed to help recognize, 
prevent, and treat SOD. Future studies are needed to assess the treatment benefit of 
agents such as calcium-channel blockers, glyceryl trinitrate, or tricyclic antidepressants 
in patients with SOD.
Keywords: pancreatitis, sphincter of Oddi, sphincter of Oddi dysfunction, functional biliary disorder, biliary colic, 
hepatic enzymes, lipase, amylase
HiSTORiCAL NOTeS AND PURPOSe OF THe Review
In 1941, Williamson wrote a letter to the British Medical Journal, concerned that “a fair number of 
people without gallbladders who are potential air raid causalities and to whom … morphine will 
probably be administered … (would), far from relieving their pain and shock … increase it” (1). The 
letter was in response to a publication by Smyth, who noted that selected drugs dilate the sphincter 
of Oddi (SO) while, “contrary to what might be expected,” morphine, codeine, and hydromorphone 
produced “spasm of the sphincter” (2). This formed the basis for the syndrome later termed SO 
dysfunction (SOD). The purpose of this paper is to review SO anatomy and physiology, SOD (includ-
ing subtypes), the effect of cholecystectomy on the SO, and the impact of exogenous compounds on 
the SO, and to provide an overview of the diagnosis and management of SOD.
STRUCTURe AND FUNCTiON OF THe SO
The SO is a muscular structure surrounding the confluence of the distal common bile duct (CBD) 
and the pancreatic duct (PD) into the ampulla of Vater (Figure 1) (3, 4). The sphincter structure 
with overlying mucosa protruding into the duodenum is called the papilla of Vater. At least three 
functions of the SO have been identified: (1) regulation of bile flow into the duodenum; (2) preven-
tion of duodenal reflux; and (3) regulation of gallbladder filling by diverting bile into the gallbladder 
with SO closure.
FigURe 1 | Sphincter of Oddi (SO) and its anatomic relationships. In the majority of patients, pancreatic and biliary secretions enter the duodenum through 
the SO. The sphincter structure with overlying mucosa protruding into the duodenum is called the papilla of Vater. The image is an endoscopic photograph of the 
duodenum at this entry site. In addition, there are individual sphincters for both the common bile duct and the pancreatic duct proximal to the SO. All the sphincters 
are neurohumorally regulated. Adapted from Gorelick et al. (5). Used with permission. Copyright, American Gastroenterological Association Institute, Bethesda, MD, 
USA.
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The physiology of the SO has been studied in both animals 
and humans. While varying species have been studied, dog, 
cat, and pig physiology are most similar to humans. It is critical 
to consider species studied when analyzing pharmacological 
data (see Medications and the Risk of SOD). In humans, basal 
pressure of the SO is 10  mmHg. Superimposed anterograde 
phasic contractions, initiated at the junction of the CBD and 
the SO and progressing into the duodenum, occur in response 
to physiologic and exogenous stimuli and result in evacuation 
of contents already present within the SO into the duodenum. 
During contraction, no additional flow from the CBD into the SO 
occurs. The SO then relaxes, allowing passive refilling of bile into 
the SO segment. Once filled, another wave of phasic contractions 
begins (6, 7). When basal pressure increases, resistance to flow 
increases, resulting in gallbladder filling and prevention of flow 
into the duodenum. When basal pressure decreases below CBD 
and PD pressures, flow into the duodenum occurs.
Sphincter of Oddi motility patterns have been defined for 
both the inter-digestive period and the digestive period. During 
the inter-digestive period, the SO has a cyclical activity pattern 
throughout all phases and the frequency increases prior to phase 
3 duodenal activity, prompting discharge of bile and pancreatic 
secretions into the duodenum (8–11). Motility during the 
digestive period involves both neural and hormonal inputs. In 
this period, there are gallbladder contractions, stimulation of 
pancreatic secretion, and SO relaxation, leading to high rates of 
bile and pancreatic secretion into the duodenum. Of note, dur-
ing the digestive period, there are different phases of the meal, 
each providing input. For example, up to 30–40% of gallbladder 
emptying and 25% of pancreatic secretion occurs during the 
cephalic phase via vagal inputs, while another 10–20% of the 
response occurs during the gastric phase via vagovagal pathways. 
However, the gallbladder empties most of its remaining contents 
and the pancreas up to 50% of its total secretion during the intes-
tinal phase, induced by the release of cholecystokinin (CCK) and 
secretin from the duodenum and proximal jejunum. Duodenal 
CCK contracts the gallbladder, relaxes the SO, and causes pan-
creatic exocrine digestive enzyme secretion via direct actions 
on CCK receptors and indirectly through cholinergic neurons. 
This is supported by the observation that atropine pretreatment 
blocks gallbladder contraction and pancreatic secretion induced 
by physiological concentrations of CCK and by a protein-fatty 
meal (12–15).
HORMONeS AND NeUROTRANSMiTTeRS 
iNvOLveD iN SO FUNCTiON
The most important hormone involved in SO function is CCK. 
CCK released from the enteroendocrine cells in response to 
a meal exerts direct hormonal effects as well as indirect effects 
by interacting with neural pathways, leading to gallbladder 
TAbLe 1 | Milwaukee classification for biliary SOD (39).
Type 1 Biliary pain associated with all three of the following:
*Serum aminotransferases that are >2 × ULN on ≥2 occasions
AND
*CBD dilation ≥10 mm on US or 12 mm on ERCP
AND
*Delayed drainage (>45 min) of contrast from the CBD on ERCP
Type 2 Biliary pain associated with one or two of the following:
*Serum aminotransferases that are >2 × ULN on ≥2 occasions
OR
*CBD dilation ≥10 mm on US or 12 mm on ERCP
OR
*Delayed drainage (>45 min) of contrast from the CBD on ERCP
Type 3 Biliary pain only
CBD, common bile duct; ERCP, endoscopic retrograde cholangiopancreatography; 
SOD, sphincter of Oddi dysfunction; ULN, upper limit of normal; US, ultrasonography.
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contraction and pancreatic enzyme secretion. CCK decreases SO 
basal pressures and inhibits phasic contractions, thereby promot-
ing anterograde flow (16, 17). Vasoactive intestinal polypeptide 
and nitric oxide, present in the intrinsic neurons of the SO, are 
involved in the relaxation response to CCK as well as the relaxa-
tion observed in the cephalic phase of the meal (18, 19).
Motilin, somatostatin, and octreotide hormonally influence SO 
function. Motilin, secreted by the M cells within the duodenum 
and jejunum, induces contraction of the smooth muscle of the 
gallbladder and stimulates bile secretion (20–22). Somatostatin, 
present in endocrine cells throughout the gastrointestinal tract, 
likely exerts inhibitory effects on both gallbladder contraction 
and relaxation of the SO (23), supported by the observation that 
50 μg intravenous octreotide, an agent that mimics somatostatin, 
causes a significant increase in SO basal pressure and frequency 
of phasic contractions (24).
wHAT iS SOD?
Sphincter of Oddi dysfunction is a clinical syndrome caused by 
SO dyskinesia (functional) or anatomic (mechanical) obstruction 
associated with abdominal pain and elevation of liver or pancre-
atic enzymes, CBD or PD dilation, or pancreatitis (25). Of note, 
the term SO dyskinesia more specifically denotes motility disor-
ders of the SO, while SOD includes both mechanical obstruction 
and SO dyskinesia. In this context, the term biliary dyskinesia has 
historically been used as a general term that included both SO 
dyskinesia and gallbladder dyskinesia (26). Since the availability 
of scintigraphy, a functional gallbladder disorder (i.e., gallbladder 
dyskinesia/dysfunction) is now recognized as a discrete entity and 
should be distinguished from SO dyskinesia (27–29). The various 
forms of primary SOD are considered functional gastrointestinal 
disorders and may occur in adults or children of any age, but 
SOD is most commonly encountered in females aged 20–50 years 
(30–32). The estimated prevalence of SOD is 1.5% in the general 
population and may be as high as 72% in patients with idiopathic 
recurrent pancreatitis based on small cohort studies (30, 32–35). 
However, its true prevalence is difficult to determine due to the 
lack of definitive biomarkers or diagnostic criteria as well as the 
multitude of secondary causes of SOD, such as fibrosis of the 
sphincteric channel (papillary stenosis and sclerosing papillitis) 
or obstructive carcinoma.
CLiNiCAL PReSeNTATiONS OF SOD
Sphincter of Oddi dysfunction can involve the biliary sphincter, 
the pancreatic sphincter, or both (25). Biliary SOD typically 
presents with recurrent biliary pain, characterized as disabling 
epigastric or right upper quadrant pain lasting 30 min to several 
hours with or without hepatic enzyme elevation. It may radiate 
to the back, shoulder, or scapula and may be accompanied by 
nausea and vomiting, mimicking a gallbladder attack. Pain is not 
consistently postprandial and is not relieved by postural changes, 
antacids, or bowel movements.
Pancreatic SOD is thought to be responsible for a portion of 
patients with recurrent episodes of acute pancreatitis. Patients 
will have mid-abdominal, pancreatic pain, radiating to the 
back, associated with elevations in serum amylase and lipase. 
Symptoms involving the pancreatic sphincter are frequently 
exacerbated by food intake. No other causes for pancreatitis are 
usually found in these patients, and they may be classified as 
having idiopathic acute recurrent pancreatitis (IARP) (36, 37). 
Toouli and colleagues compared the SO manometric pressures in 
28 patients with IARP with those of 10 controls and found that 
more than 57% of patients with IARP had elevated SO pressures 
(38). However, the true incidence of pancreatitis caused by SOD 
is unknown. When both the pancreas and biliary sphincters are 
involved, the abdominal pain may be more diffuse and both 
hepatic and pancreatic enzyme elevation can occur.
DiAgNOSiS OF SOD
The diagnosis of SOD is challenging, but history, physical exam, 
relevant labs, and imaging studies are critical. Some view SOD as 
a structural abnormality while others view it as a functional dis-
order. A classification system for SOD as a structural abnormality 
was established in 1988. Initially known as the Hogan–Geenan 
SOD classification and later modified as the Milwaukee classifica-
tion, it classifies SOD patients into types 1, 2, and 3 based on 
clinical presentation as well as laboratory and/or imaging abnor-
malities (see Table 1 for biliary SOD and Table 2 for pancreatic 
SOD) (26, 39). Table 3 lists the Rome III criteria for SOD as a 
functional disorder (25). These criteria were meant to make the 
diagnostic evaluation more applicable to clinical practice and, 
whenever possible, avoid invasive procedures by emphasizing 
non-invasive imaging of CBD diameter. Earlier studies showed 
higher rates of depression, obsessive compulsive disorders, 
and anxiety in patients with type 3 SOD when compared with 
controls (40). Conversely, a randomized, controlled trial of SOD 
type 3 patients showed that psychosocial disability in patients 
with severe symptoms may not be different than in the general 
population (41).
OTHeR evALUATiONS FOR SOD
In the past, non-invasive testing to diagnose SOD included quan-
titative hepatobiliary scintigraphy to assess biliary flow (42–44), 
TAbLe 3 | Rome iii classification of SOD.
Epigastric or right upper quadrant abdominal pain that is associated with ≥1 of 
the following:
≥30 min in duration
Recurrent symptoms occurring at variable intervals (not daily)
Occurring on ≥1 occasion in the past 12 months
Pain that builds up to a steady level
Pain that is moderate to severe enough to interrupt daily activity
No evidence of structural abnormalities
SOD, sphincter of Oddi dysfunction.
TAbLe 2 | Milwaukee classification for pancreatic SOD (39).
Type 1 Pancreatic type pain associated with all three of the following:
*Serum amylase or lipase that is >2 × ULN on ≥2 occasions
AND
*Pancreatic duct (PD) dilation >6 mm in head and >5 mm in body
AND
*Delayed drainage (>9 min) of contrast from the PD on ERCP
Type 2 Pancreatic type pain associated with one or two of the following:
*Serum amylase or lipase that is >2 × ULN on ≥2 occasions
OR
*PD dilation >6 mm in head and >5 mm in body
OR
*Delayed drainage (>9 min) of contrast from the PD on ERCP
Type 3 Pancreatic type pain only
ERCP, endoscopic retrograde cholangiopancreatography; SOD, sphincter of Oddi 
dysfunction; ULN, upper limit of normal.
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endoscopic ultrasound, or magnetic resonance cholangiopan-
creatography with secretin injection (45). However, these tests 
are neither sensitive nor specific for SOD.
Manometry of the SO is considered the gold-standard test 
to diagnose SOD (46, 47). During SO manometry, a catheter is 
inserted into the duodenum and calibrated to 0  mmHg. Next, 
the catheter is inserted into the CBD and/or PD for 30 s; basal 
pressures ≥40 mmHg indicate SOD (48). Prior to the procedure, 
patients should avoid agents that inhibit SO function, such 
as anticholinergics, nitrates, and calcium-channel blockers, 
and those that stimulate it, such as opiates and cholinergics. 
There are limitations to SO manometry: first, it requires skilled 
endoscopists with special equipment not readily available at most 
institutions; second, it is associated with up to 30% increased risk 
of iatrogenic pancreatitis (49); and finally, isolated point in time 
pressure measurements obtained during SO manometry may 
not reflect the dynamic nature of the SO, leading to difficulties 
in applying the results. Therefore, the use of SO manometry as a 
gold-standard test remains controversial. Furthermore, isolated 
basal pressures cannot differentiate between SO motor dis-
turbances and anatomical stenosis. Of note, manometry is not 
confirmatory in 13–40% of patients ultimately diagnosed with 
type 1 SOD (50–53).
NON-PHARMACOLOgiC RiSK  
FACTORS FOR SOD
Certain populations, such as patients who have undergone chol-
ecystectomy (32), are predisposed to SOD (31). In subjects with 
an intact gallbladder, CCK inhibits SO phasic wave activity, but 
6 months after cholecystectomy, CCK fails to inhibit this activity 
(54). Sherman reported that 10–20% of postcholecystectomy 
patients experience biliary colic and a review of patients with 
postcholecystectomy pain found that 9–51% met diagnostic 
criteria for SOD after cholecystectomy (31). Overall, ~1.5% of 
patients develop SOD after cholecystectomy (25, 55).
It is postulated that the gallbladder acts as a backflow reser-
voir for bile to dampen sudden increases in pressure resulting 
from physiologic or extra-physiologic ductal obstruction 
(56–59). Luman and colleagues demonstrated that patients with 
postcholecystectomy syndrome had elevated basal SO pressure, 
retrograde phasic wave contraction, and an increase in phasic 
wave frequency greater than seven contractions per minute 
(tachyoddia) (60). It is unclear if postcholecystectomy patients 
are susceptible to developing SOD because of elevated pressures, 
altered SO motility, or both.
Sphincter of Oddi dysfunction has also been linked to agenesis 
of the gallbladder (61), preoperative cholelithiasis (25), gallstone 
lithotripsy (62), liver transplantation (63), and alcoholism (64). 
Delayed emptying of the biliary tract related to hypothyroidism 
suggests another risk factor for SOD (65, 66). Additionally, sub-
jects with hypothyroidism have an increased risk of gallstones, 
thought secondary to the absence of thyroxine’s relaxing effect 
on the SO (67).
Patients with irritable bowel syndrome (IBS) may be at an 
increased risk of SOD. Evans and colleagues reported that patients 
with IBS who undergo cholecystectomy are more likely to dem-
onstrate a blunted response to sphincter-relaxing properties of 
CCK compared with postcholecystectomy patients without IBS 
(68). The prevalence and incidence of SOD among IBS patients 
is unclear because of the difficulty in diagnosing SOD in IBS 
patients due to overlap of symptoms (69).
Sphincter of Oddi dyskinesia occurs more frequently in women 
than in men, and animal models offer some insight. In the prairie 
dog, CCK increases SO phasic wave frequency in both sexes, but 
amplitude increases were significantly greater in females than in 
males (70). Further support for gender differences was shown by 
estrogen suppression of SO wave frequency in prairie dogs, while 
progesterone’s effect on the SO is unclear (71).
MeDiCATiONS AND THe RiSK OF SOD
Exogenous agents play an additive role in populations at risk 
for SOD. Opiates are known to alter flow through the SO. In the 
absence of a gallbladder, morphine, meperidine, and pentazocine 
increase biliary pressure in opossums (56). Behar and Biancani 
found that leucine and methionine-enkephalin caused an initial 
contraction followed by a prolonged relaxation of the cat SO, 
suggesting that endogenous delta opioid agonism is involved 
in increasing flow through the sphincter (72, 73). Importantly, 
the mu antagonist naloxone had no effect on morphine-induced 
increases in basal SO pressure but did diminish morphine’s effect 
on SO phasic wave frequency and amplitude. The naloxone 
inhibitory effect suggests that the mu opioid receptor is involved, 
while the absence of naloxone antagonism on SO basal pressure 
may be non-mu opioid receptor mediated.
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Thus, morphine increases the amplitude and frequency of the 
phasic wave (via mu opioid receptors) as well as basal pressure 
(via non-mu opioid receptors) of the SO (74, 75). These effects 
have also been demonstrated with fentanyl (76) and codeine (77). 
Morphine shows limited effect on the SO in patients prior to chol-
ecystectomy, whereas it caused a notable rise in basal sphincter 
pressure postoperatively (59). Since morphine can precipitate 
abdominal pain not related to the SO, Holtzer and Hulst proposed 
a “morphine-enzyme-pain” provocation test: pain accompanied 
by at least a doubling of the alanine aminotransferase 8 h after 
administration indicated SO dyskinesia (75). The magnitude 
of transaminase elevation associated with morphine has been 
reported as high as 65 times above normal in patients without 
a gallbladder (78). Mousavi and colleagues demonstrated that 
chronic opiates induce SOD compared with case controls (79), 
and several authors have documented asymptomatic, dilated 
CBDs in patients addicted to opiates (80–82).
The effects of tramadol, buprenorphine, pentazocine, and 
pethidine have been evaluated with SO manometry. Pentazocine 
increased the duration of sphincter contraction and ductal 
pressure while tramadol, buprenorphine, and pethidine did 
not (83, 84). Meperidine was shown to increase the pancreatic 
component, biliary component, and SO phasic frequency and to 
decrease phasic duration in 3/47 patients studied with manom-
etry (85). Eluxadoline, a mixed opioid receptor modulator with 
mu and kappa opioid receptor agonist effects and delta opioid 
receptor antagonist effects that was recently approved by the 
FDA for IBS with diarrhea, was linked to a small number of 
non-serious cases of SO spasm and pancreatitis in the phase 3 
studies of this medication (86). Among 1,619 patients exposed 
to eluxadoline in these trials, 8 (0.49%) developed SO spasm and 
5 (0.31%) developed pancreatitis, 1 case of which was attributed 
to SO spasm. Importantly, all cases of eluxadoline-associated SO 
spasm occurred in patients who did not have gallbladders and 
were more common with 100  mg twice daily (BID) compared 
with 75  mg BID. One case of pancreatitis was associated with 
biliary sludge while the other three were associated with heavy 
alcohol use.
Opiates have been reported to incite pancreatitis, and their 
effects on the SO represent the most likely etiology (87). The mu 
antagonist naloxone reduces the severity of pancreatitis induced 
by intraductal injection of trypsin–bile mixture in dogs. In the 
opossum, Chen and colleagues induced pancreatitis when they 
combined simulated SOD (by PD ligation mimicking the opiate 
effect) with pharmacologically stimulated pancreatic secretion 
(88). In humans, drug rechallenge (89, 90) with heroin (91, 92), 
codeine (93–95), tapentadol,1 and loperamide (96–99) have estab-
lished a link with these drugs and acute pancreatitis. Loperamide 
inhibits the normal contractile response of the gallbladder to 
CCK (100) and, in patients with short bowel syndrome, reduces 
pancreatic and biliary output (101). The mechanism of opiate-
induced pancreatitis is assumed to be related to their action on 
the SO; some suggest that loperamide’s effect may be different 
1 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022304s000_ 
MedR_P2.pdf.
as it is structurally more related to haloperidol (102) than to 
morphine.
THeRAPY FOR SOD
Certain exogenous agents relax the SO, reducing its pressure and 
resistance. This includes calcium-channel blockers (103, 104), 
tricyclic antidepressants (105), Botox®, glyceryl trinitrate (GTN), 
and somatostatin. Nifedipine has been shown to reverse opiate-
induced effects on the SO (106) and improve pain associated with 
SOD in a short-term study (103). Injection of Botox® into the 
SO via sclerotherapy needle reduced sphincter pressure by 50% 
for 4 months and was followed by 50% improvement in bile flow 
in two patients with postcholecystectomy pain and elevated SO 
pressures (107). GTN has been used to assist removal of lodged 
CBD stones without endoscopic papillary dilatation or endoscopic 
papillotomy (108) and decreased both basal SO pressure as well 
as the amplitude and frequency of SO phasic wave contractions 
in a non-randomized, controlled clinical trial (108). Intravenous 
somatostatin was shown to reduce mean SO (109) basal pressures 
in patients with acute alcoholic pancreatitis (64).
One prospective study of patients with biliary SOD (defined by 
clinical and laboratory data) evaluated the combination of a low-
dose tricyclic antidepressants, nifedipine, and GTN. If there was 
no improvement after 3–6 months, patients were offered biliary 
sphincterotomy. Fifty-one percent of the patients (76% with type 
3) had symptomatic resolution or improvement on medical ther-
apy alone, 12% had symptomatic improvement or resolution with 
sphincterotomy, and 10% had improvement with both medical 
therapy and sphincterotomy (110). Although promising, opiates 
were allowed during this study, confounding the determination of 
symptom improvement due solely to interventions.
The most commonly used non-pharmacologic treatment 
for SOD has been endoscopic sphincterotomy for patients with 
types 1 and 2 biliary SOD and pancreatic SOD. Pain relief has 
been shown in 90% of patients with type 1 biliary SOD and 70% 
of patients with type 2. However, it is not effective, and may 
be harmful, in patients with type 3. The evaluating predictors 
and interventions in sphincter of Oddi dysfunction trial was a 
landmark study for treatment of type 3. This was a multicenter, 
sham-controlled, randomized trial in patients with pain after 
cholecystectomy, without abnormalities on imaging or labora-
tory studies, and no prior SO treatment. Participants underwent 
sphincterotomy or sham sphincterotomy for abdominal pain. 
The investigators concluded that performing a sphincterotomy 
in patients with type 3 SOD was ineffective (111). As a result, 
endoscopists are shifting away from performing sphincterotomy 
in these patients.
There are limited studies evaluating the role of PD stenting 
and sphincterotomy in patients with pancreatic SOD. Jacob 
and colleagues found a significant reduction in the incidence of 
recurrent acute pancreatitis in those who were stented (112). Coté 
and colleagues evaluated the role of endoscopic dual (biliary and 
pancreatic) sphincterotomy vs. biliary sphincterotomy alone in 
patients with IARP and found that both types of sphincterotomies 
had similar effects in preventing recurrence of acute pancreatitis 
(113). Another study found no difference in preventing recurrent 
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pancreatitis when dual sphincterotomy was compared with either 
pancreatic or biliary sphincterotomy (114).
CONCLUSiON
Sphincter of Oddi dysfunction denotes impaired fluid flow 
through the SO, either by a fixed stenosis or disordered muscular 
control (dyskinesia). Gallbladder function appears to play a 
critical role in SO mechanics, and patients without a gallbladder 
are more likely to experience SOD. Other potential contribut-
ing factors include female gender, hypothyroidism, IBS, prior 
pancreatitis, and exogenous medications. The data supporting a 
link between opiates and SOD are clear and reproducible, and the 
resulting clinical syndromes, especially in postcholecystectomy 
patients, include abdominal pain with sudden, yet reversible, 
elevations in liver enzymes as well as acute pancreatitis. Different 
opiate agents appear to have varying effects on SO basal and pha-
sic contractions. While exogenous mu opioid agonists negatively 
affect flow through the SO, endogenous enkephalins (possibly 
delta agonists) may improve flow through the sphincter.
While there is some evidence that nifedipine, Botox®, and 
GTN may improve flow through the SO and mitigate SOD 
symptoms, the efficacy of these agents remains to be proven in 
sufficiently large, randomized, and controlled trials. Endoscopic 
sphincterotomy remains the treatment of choice for select patients 
confidently diagnosed with SOD. However, increased awareness 
by caregivers of risk factors for SOD provides opportunities for 
diagnosis and intervention, including avoidance of potential 
precipitating agents, especially in the absence of a gallbladder.
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